The Anglo-Swedish pharma giant said that it will initiate a tender offer to acquire all of U.S.-listed clinical-stage biopharmaceutical company CinCor’s CINC outstanding shares.
You are here: Home / Top Stories / Dow Jones Newswires: AstraZeneca agrees to buy U.S.-based CinCor in deal valued at $1.3 billion